Immunotherapy for prion diseases is typically based on the assumption that PrP-reactive immunoglobins offer therapeutic benefit through either destruction of the infectious isoform, neutralization of PrPSc to prevent further misfolding, or depletion of PrPC to eliminate the substrate required for disease propagation, or a combination of these factors. This evidence concerns the gene PRNP and prion disease.